RT Journal Article
T1 Biomaterials to suppress cancer stem cells and disrupt their tumoral niche
A1 García Mazás, Carla
A1 Csaba, Noemi Stefania
A1 García Fuentes, Marcos
K1 Cancer stem cells
K1 Tumor initiating cells
K1 Tumor niche
K1 Biomaterials
K1 Tissue engineering
K1 Drug delivery
K1 Nanomedicine
AB Lack of improvement in the treatment options of several types of cancer can largely be attributed to the presence of a subpopulation of cancer cells with stem cell signatures and to the tumoral niche that supports and protects these cells. This review analyses the main strategies that specifically modulate or suppress cancer stem cells (CSCs) and the tumoral niche (TN), focusing on the role of biomaterials (i.e. implants, nanomedicines, etc.) in these therapies. In the case of CSCs, we discuss differentiation therapies and the disruption of critical signaling networks. For the TN, we analyze diverse strategies to modulate tumor hypervascularization and hypoxia, tumor extracellular matrix, and the inflammatory and tumor immunosuppressive environment. Due to their capacity to control drug disposition and integrate diverse functionalities, biomaterial- based therapies can provide important benefits in these strategies. We illustrate this by providing case studies where biomaterial-based therapies either show CSC suppression and TN disruption or improved delivery of major modulators of these features. Finally, we discuss the future of these technologies in the framework of these emerging therapeutic concepts
PB Elsevier
SN 0378-5173
YR 2017
FD 2017-05-25
LK http://hdl.handle.net/10347/15728
UL http://hdl.handle.net/10347/15728
LA eng
NO Garcia-Mazas, C., Csaba, N. and Garcia-Fuentes, M. (2017). Biomaterials to suppress cancer stem cells and disrupt their tumoral niche. International Journal of Pharmaceutics, 523(2), pp.490-505. Disponible en: http://dx.doi.org/10.1016/j.ijpharm.2016.12.013
NO Fundación BBVA, Proyectos de Investigación en Biomedicina (2014-PO0110) Ministerio de Economía y Competitividad (SAF2014-58189-R, FEDER Funds)
DS Minerva
RD 24 abr 2026